SCHEMBL7879928

SCHEMBL7879928

CCN(CC)CCOc1ccc2cc(C(=O)N=C(N)NC)[nH]c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.46
MAOB P27338 4/20 0.44
PDGFRB P09619 2/20 0.41
PDGFRA P16234 2/20 0.41
CHEK1 O14757 1/20 0.41
MAP4K4 O95819 1/20 0.41
LCK P06239 1/20 0.41
CSF1R P07333 1/20 0.41
PIM1 P11309 1/20 0.41
PHKG2 P15735 1/20 0.41
MARK3 P27448 1/20 0.41
KDR P35968 1/20 0.41
CLK2 P49760 1/20 0.41
GSK3A P49840 1/20 0.41
ITK Q08881 1/20 0.41
MAP4K2 Q12851 1/20 0.41
DYRK1A Q13627 1/20 0.41
MARK2 Q7KZI7 1/20 0.41
PIM3 Q86V86 1/20 0.41
MINK1 Q8N4C8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7873242 0.95 MAOB (0.45) FLT3MAOBPDGFRBPDGFRACHEK1
SCHEMBL7877764 0.90 FLT3 (0.58) FLT3PDGFRBPDGFRACHEK1MAP4K4
SCHEMBL7881223 0.87 PDGFRB (0.53) FLT3PDGFRBPDGFRACHEK1KMT2A
SCHEMBL7879728 0.86 FLT3 (0.43) FLT3PDGFRBPDGFRAKMT2A
Hydrochloric Acid SCHEMBL7881414 0.85 FLT3 (0.42) FLT3PDGFRBPDGFRAKMT2A
SCHEMBL7873709 0.85 HRH3 (0.47) FLT3MAOBPDGFRBPDGFRAMAPT
Hydrochloric Acid SCHEMBL8628104 0.85 FLT3 (0.41) FLT3PDGFRBPDGFRAKMT2A
Hydrochloric Acid SCHEMBL7879744 0.85 FLT3 (0.41) FLT3PDGFRBPDGFRAKMT2A
SCHEMBL7873756 0.84 MAOB (0.37) FLT3MAOBCHEK1MAP4K4LCK
SCHEMBL7873807 0.83 FLT3 (0.40) FLT3MAOBPDGFRBPDGFRAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed